BACKGROUND: Adults with malignant glioma, especially the most common subtype, glioblastoma multiforme, have an unacceptably poor outcome with current therapies. Malignant gliomas are amongst the most angiogenic of cancers, and VEGF is the dominant angiogenic mediator in these tumors. OBJECTIVE: To summarize the clinical experience of VEGF-directed treatment for malignant glioma. METHODS: We reviewed the completed, ongoing and planned clinical trials evaluating anti-VEGF strategies for malignant glioma patients. RESULTS/ CONCLUSIONS: Recent studies incorporating anti-VEGF agents plus cytotoxic therapy among recurrent malignant glioma patients have achieved unprecedented improvements in radiographic response, time to progression and survival. Furthermore, acceptable toxicity was observed. Hence, a major current focus in neuro-oncology is to further develop antiangiogenic strategies for this desperate patient population.
BACKGROUND: Adults with malignant glioma, especially the most common subtype, glioblastoma multiforme, have an unacceptably poor outcome with current therapies. Malignant gliomas are amongst the most angiogenic of cancers, and VEGF is the dominant angiogenic mediator in these tumors. OBJECTIVE: To summarize the clinical experience of VEGF-directed treatment for malignant glioma. METHODS: We reviewed the completed, ongoing and planned clinical trials evaluating anti-VEGF strategies for malignant gliomapatients. RESULTS/ CONCLUSIONS: Recent studies incorporating anti-VEGF agents plus cytotoxic therapy among recurrent malignant gliomapatients have achieved unprecedented improvements in radiographic response, time to progression and survival. Furthermore, acceptable toxicity was observed. Hence, a major current focus in neuro-oncology is to further develop antiangiogenic strategies for this desperate patient population.
Authors: Peter Vajkoczy; Mohammad Farhadi; Andreas Gaumann; Regina Heidenreich; Ralf Erber; Andreas Wunder; Jörg C Tonn; Michael D Menger; Georg Breier Journal: J Clin Invest Date: 2002-03 Impact factor: 14.808
Authors: James M Provenzale; Gin R Wang; Thomas Brenner; Jeffrey R Petrella; A Gregory Sorensen Journal: AJR Am J Roentgenol Date: 2002-03 Impact factor: 3.959
Authors: Jack P Rock; David Hearshen; Lisa Scarpace; David Croteau; Jorge Gutierrez; James L Fisher; Mark L Rosenblum; Tom Mikkelsen Journal: Neurosurgery Date: 2002-10 Impact factor: 4.654
Authors: Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge Journal: Proc Natl Acad Sci U S A Date: 2002-08-12 Impact factor: 11.205
Authors: Hon-Kit Andus Wong; Rachid El Fatimy; Courtney Onodera; Zhiyun Wei; Ming Yi; Athul Mohan; Sindhuja Gowrisankaran; Priya Karmali; Eric Marcusson; Hiroaki Wakimoto; Robert Stephens; Erik J Uhlmann; Jun S Song; Bakhos Tannous; Anna M Krichevsky Journal: Mol Ther Date: 2015-04-23 Impact factor: 11.454
Authors: Lee W Jones; Allan H Friedman; Miranda J West; Stephanie K Mabe; Jennifer Fraser; William E Kraus; Henry S Friedman; Maura I Tresch; Nancy Major; David A Reardon Journal: Cancer Date: 2010-02-01 Impact factor: 6.860
Authors: Csanad G Varallyay; Leslie L Muldoon; Seymur Gahramanov; Yingjen J Wu; James A Goodman; Xin Li; Martin M Pike; Edward A Neuwelt Journal: J Cereb Blood Flow Metab Date: 2009-01-14 Impact factor: 6.200
Authors: Yi Lin; Yong Chen; Yongzhi Wang; Jingxuan Yang; Vivian F Zhu; Yulun Liu; Xiaobo Cui; Leon Chen; Wei Yan; Tao Jiang; Georgene W Hergenroeder; Stephen A Fletcher; Jonathan M Levine; Dong H Kim; Nitin Tandon; Jay-Jiguang Zhu; Min Li Journal: Neuro Oncol Date: 2013-04-17 Impact factor: 12.300